ABSTRACT
Gastric cancer is the fourth most common cancer and the second most common cause of cancer death worldwide. The 5-year overall survival rate of gastric cancer is only 15% to 20%. [1] [2] [3] Early diagnosis is the key factor determining treatment outcome, and surgery is the first choice of treatment. The rate of diagnosis of early gastric cancer has increased annually with the development of a screening test 4, 5 ; however, most patients with gastric cancer are still diagnosed in the late stage of disease when the opportunity for surgery has passed because of the lack of obvious clinical symptoms in the early stage. 6 Although chemotherapy has shown some survival benefit, most chemotherapy regimens have limitations, and efficacies are not satisfactory. 7, 8 Biomarkers with high sensitivity and specificity are imperative for improving disease prevention and diagnosis, development of targeted therapies, and prediction of prognosis. 9 Consequently, the discovery of valuable biomarkers has become a major focus of current research. By exploring The Cancer Genome Atlas database, we identified a number of novel protein molecules that are expressed differentially between tumor and normal tissues.
One such protein is fibrinogen C domain containing 1 (FIBCD1), a protein of 461 amino acids. 10 FIBCD1 is a newly identified acetyl group recognition receptor, with a known ligand of chitin; it binds acetyl groups on chitin via a fibrinogen-like recognition domain. 11 The FIBCD1 gene is located on human chromosome 9q34. 1. 12 FIBCD1 is expressed mainly on intestinal epithelial cells and airway epithelial cells and is also detected on epithelial cells lining the salivary ducts. To date, the expression of FIBCD1 protein and its association with clinicopathologic features in gastric cancer have not been explored. In this retrospective study, we examined FIBCD1 gene transcripts and protein expression in gastric cancer and normal tissue samples by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and tissue microarray immunohistochemistry analysis (TMA-IHC), respectively, and analyzed the correlation between FIBCD1 and patients' clinical characteristics and its prognostic implications.
Materials and Methods

Tumor Tissues and Clinical Data
Gastric cancer samples were collected in the biological sample bank of the Affiliated Hospital of Nantong University from June 2004 to July 2009. Tumor tissues obtained from surgery were fixed in formalin and embedded in paraffin and then examined by at least two pathologists (C.J. and W.W.). This study included 520 gastric cancer samples, 24 chronic gastritis tissues, 46 intestinal metaplasia tissues, 33 low-grade intraepithelial neoplasia tissues, 24 high-grade intraepithelial neoplasia tissues, and 59 surgical margins from patients with gastric cancer. The clinical data of all patients were recorded in detail, including age, sex, tumor location, tumor size, preoperative serum carcinoembryonic antigen (CEA) level, preoperative serum CA19-9 level, human epidermal growth factor receptor 2 (HER-2) level, tumor invasion depth, lymph node metastasis, tumor differentiation, and TNM stage. None of the patients received chemotherapy, radiotherapy, or immunotherapy before surgery. Written informed consent for publication of this study and any accompanying images were obtained from the patients. The study protocol was approved by the Ethics Committee of the Human Research Ethics Committee of the Affiliated Hospital of Nantong University, and all experiments were performed in accordance with approved guidelines of the Affiliated Hospital of Nantong University.
qRT-PCR
Total RNA was isolated from 27 pairs of fresh-frozen tissues. The 27 pairs of tumor tissue and benign surgical marginal tissue were diagnosed definitely by frozen section in 2016. Total RNA was isolated and purified from these fresh-frozen tissues using the RNeasy Mini Kit and QiaShredders (Qiagen, Sussex, UK). Complementary DNA was generated from total RNA using a reverse transcription kit (Fermentas, Foster City, CA) according to the manufacturer's instructions. Quantitative polymerase chain reaction (PCR) was performed on a Biorad iCycler (Biorad, Gladesville, Australia). The primers for FIBCD1 were as follows: forward primer (5´-GTGTGGGGTTCCGTTCTC-3´) and reverse primer (5´-CCAGTGGTGCCAAGTCAA-3´). 18S ribosomal RNA (rRNA) (Life, Carlsbad, CA) served as an endogenous control. Amplification conditions were 6 minutes at 95°C for denaturation followed by 35 cycles of 30 seconds at 95°C and 1 minute at 60°C.
Tissue Microarray Construction and Immunohistochemistry Analysis
TMA-IHC was performed to determine FIBCD1 protein expression in 706 archived gastric tissue blocks, including 520 gastric cancer tissues, 24 chronic gastritis tissues, 46 intestinal metaplasia tissues, 33 low-grade intraepithelial neoplasia tissues, 24 high-grade intraepithelial neoplasia tissues, and 59 surgical margins in gastric cancer. Core tissue biopsy specimens (2 mm in diameter) taken from individual paraffin-embedded sections were arrayed in new recipient paraffin blocks by using a tissue microarray system (Quick-Ray, UT06; UNITMA, Seoul, Korea). Sections from arrayed blocks were sliced into 4-μm sections and placed on Superfrost-charged glass microscope slides. Sections were stained with a polyclonal rabbit anti-FIBCD1 antibody (dilution 1:100) (Atlas Antibodies, Bromma, Sweden; HPA053898) at 4°C overnight, followed by incubation with biotinylated anti-rabbit antibody as a secondary antibody at room temperature for 2 hours.
Positive staining of FIBCD1 was localized predominantly in the nuclei of gastric cells ❚Image 1❚. However, two chronic gastritis tissues and three intestinal metaplasia tissues showed positive staining of FIBCD1, which localized in the cytoplasm and cytomembrane. But this staining did not achieve statistical significance; therefore, we only discussed tissues with positive staining in nuclei. The staining intensity and percentage scores of FIBCD1 for the core on each chip were evaluated by at least two pathologists (C.J. and W.W.). Staining intensity was scored as follows: 0 (negative), 1 (weakly positive), 2 (moderately positive), and 3 (strongly positive). The positive rate of FIBCD1 was scored, ranging from 0 to 100. The product of the intensity score and the percentage were calculated, ranging from 0 to 300, and defined as the final immunohistochemistry (IHC) score. The cutoff value for the FIBCD1 expression data was set by the X-tile software program (Rimm Laboratory, Yale University; http://www.tissuearray.org/rimmlab).
14 The optimal cutoff value of FIBCD1 protein expression was identified based on the maximum χ 2 value estimated by log-rank χ 2 statistics with regard to overall survival. We chose 150 as the cutoff point: a score of 0 to 150 was regarded as low expression while 150 to 300 was regarded as high expression. 
Bioinformatics Analysis
We further explored the effect of FIBCD1 messenger RNA (mRNA) expression on survival of patients with gastric cancer. The prognostic implication of FIBCD1 was estimated using Kaplan-Meier plotter (KM plotter), an online survival analysis tool. The KM plotter includes transcriptomic data of 1,065 patients with gastric cancer (54,675 genes), with a mean follow-up period of 33 months.
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Statistical Analysis
qRT-PCR data were compared between two groups using the Student t test. The correlation between the expression of FIBCD1 and clinicopathologic features was calculated with χ 2 tests. We used univariate and multivariate Cox regression models to determine significant prognostic factors. The Kaplan-Meier method was used to perform survival analysis. For all analyses, a P value less than .05 was regarded as significant. Data analysis was performed using SPSS 20 software package and STATA 12.0 (SPSS, Chicago, IL).
Results
FIBCD1 mRNA Level Was Significantly Higher in Gastric Cancer Tissues Than in Normal Tissues
To compare the expression level of FIBCD1 mRNA in gastric cancer and normal tissues, we isolated total RNA from 27 pairs of cancerous and adjacent normal tissues and performed quantitative PCR. The mean ± standard deviation FIBCD1 mRNA expression in cancerous tissue and adjacent normal tissue was 0.6308 ± 0.1988 and 0.1615 ± 0.04391, respectively. The expression level of FIBCD1 mRNA in cancerous tissues was significantly higher than that in adjacent tissues (P < .05; ❚Figure 1❚).
FIBCD1 Protein Expression in Gastric Cancer by IHC
High FIBCD1 expression localized in nuclei was observed in 328 (63.07%) of 520 gastric cancer tissues compared with three (13.6%) of 22 for chronic gastritis, eight (18.6%) of 43 for intestinal metaplasia, nine (27.27%) of 33 for low-grade intraepithelial neoplasia, 12 (50.0%) of 24 for high-grade intraepithelial neoplasia, and nine (15.25%) of 59 for surgical margin in patients with gastric cancer ❚Table 1❚. FIBCD1 expression level was significantly higher in gastric cancer than in chronic gastritis, intestinal metaplasia, low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia, and surgical margin (patients with gastric cancer) (Pearson χ 2 = 97.788, P < .001). 
Association of FIBCD1 Expression With Clinical Characteristics
The association between FIBCD1 expression and clinical characteristics of gastric cancer is shown in ❚Table 2❚. High expression of FIBCD1 was correlated with age (P = .011), tumor status (T) (P < .001), lymph node (N) (P = .005), metastasis (M) (P = .035), TNM stage (P < .001), level of preoperative serum CEA (P = .002), and the expression of HER-2 (P < .001) ( Table 2) . FIBCD1 expression had no significant association with sex, histologic type, tumor differentiation, or preoperative serum CA19-9 level ( Table 2) .
Overexpression of FIBCD1 Predicts Poor Prognosis in Gastric Cancer
Prognostic factors in patients with gastric cancer were analyzed by univariate and multivariate analysis. In univariate analysis, a number of factors showed a significant association with overall survival, including high expression of FIBCD1 (hazard ratio [HR], 3.609; P < .001), older age (HR, 1.295; P = .040), histologic type (HR, 1.118; P = .038), differentiation (HR, 1.306; P = .003), TNM stage (HR, 1.507; P < .001), tumor status (HR, 1.995; P < .001), lymph node status (HR, 1.709; P < .001), metastasis (HR, 3.594; P < .001), CEA level (HR, 1.790; P < .001), and © American Society for Clinical Pathology CA19-9 level (HR, 2.449; P < .001) ❚Table 3❚. In multivariate analysis, high expression of FIBCD1 (HR, 2.725; P < .001), advanced TNM stage (HR, 1.549; P < .001), and high CA19-9 level (HR, 1.645; P = .030) were independent prognostic factors for poor prognosis (Table 3) . KaplanMeier survival analysis demonstrated that patients with gastric cancer with high FIBCD1 expression, advanced TNM stage, and high CA19-9 level had a significantly poorer prognosis ❚Figure 2❚. Consistent with these results, the KM plotter indicated that high FIBCD1 expression was significantly correlated with inferior overall survival compared with low FIBCD1 expression (log-rank test: P < .001; ❚Figure 3❚).
Discussion
FIBCD1 has not been well investigated, and little is known about its characteristics and biological functions. Our study revealed that high FIBCD1 expression correlated with poor prognosis in patients with gastric cancer. FIBCD1 is expressed in a large proportion of the gastrointestinal tract. The active form of FIBCD1 is a 55-kDa homotetramer assembled by disulfide linkages. FIBCD1 is a pattern recognition receptor. The ectodomain of FIBCD1 consists of a polycationic region, a coiled-coil region, and a C-terminal fibrinogen-like recognition domain. 16 The mechanism of FIBCD1 action is 
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❚Figure 2❚ Kaplan-Meier survival curves of patients with gastric cancer. A, Patients with high fibrinogen C domain containing 1 (FIBCD1) levels (green line, 1) had significantly worse overall survival than patients with low or no FIBCD1 levels (blue line, 0). P < .001 by log-rank test. B, Patients with advanced TNM stage had significantly shorter survival than patients with early TNM stage. P < .001 by log-rank test. C, Overall survival in patients with high CA19-9 expression (green line, 1) was worse than that in patients with low or no CA19-9 expression (blue line, 0). P < .001 by log-rank test. Others: papillary adenocarcinoma, four cases; adenosquamous carcinoma, three cases; squamous cell carcinoma, three cases; neuroendocrine carcinoma, two cases. FIBCD1 is a calcium-dependent, high-affinity acetyl group-binding receptor that binds acetylated components, including chitin, which has been shown to have great relevance to the occurrence and development of allergies. 19 Chitin is a natural polymer composed of β-(1-4)-linked N-acetyl glucosamine and the second most abundant biopolymer after cellulose worldwide. 20 Chitin is sensed primarily in the lungs or gut, where it activates a variety of innate (eosinophils, macrophages) and adaptive (interleukin 4/interleukin 13-expressing T helper type 2 lymphocytes) immune cells. 21 Vertebrates are exposed to chitins when they are infected with fungi or nematodes or ingest certain foods. 22 Chitin is typically associated with allergic and parasitic worm immune responses. 23, 24 By controlling exposure of the intestine to chitin, FIBCD1 plays an important role in immune response modulation and the immune defense against fungi and parasites. [25] [26] [27] FIBCD1 is also located in the epithelium membrane of the small intestine, suggesting a relationship between FIBCD1 and the development of inflammatory bowel diseases. 28 In addition, FIBCD1 is also expected to be a signaling protein because of the presence of two potential phosphorylation sites in its cytoplasmic region 11 ; however, the signaling pathway of FIBCD1 is currently unclear.
In this study, we examined the expression of FIBCD1 mRNA and protein in gastric cancer and normal tissues. qRT-PCR analysis demonstrated that mRNA expression of FIBCD1 in gastric cancer tissues was higher than that in normal tissues. IHC analysis further confirmed increased expression of FIBCD1 protein in gastric cancer tissues compared with normal tissues. Moreover, we demonstrated that overexpression of FIBCD1 correlates with age, TNM stage, serum CEA level, and HER-2 level. Finally, we found that FIBCD1 was an independent predictor for the prognosis of gastric cancer in our study population.
Our results indicated that FIBCD1 expression in gastric cancer might be different between age groups; in particular, overexpression of FIBCD1 was more common in older patients. It is generally known that TNM tumor stage is the most important prognostic factor for patients with gastric cancer. 29 Our study shows that positive FIBCD1 staining is significantly related to TNM stage. Increased FIBCD1 expression was related to tumor invasion depth and metastatic processes of gastric cancer and also significantly correlated with poor survival outcomes. HER-2 ❚Figure 3❚ Bioinformatics analysis. The Kaplan-Meier plotter showed that patients with high tumor fibrinogen C domain containing 1 levels had significantly reduced survival compared with those with low expression levels (n = 1,065; logrank test: P < .001). Hazard ratio = 1.84 (range, 1.42-2.38). is an important biomarker for therapeutic assessment of gastric with HER-2 protein overexpression. 30 Our results show that FIBCD1 expression in gastric cancer has a correlation with HER-2. The KM plotter further validated that high FIBCD1 expression conferred reduced survival in patients with gastric cancer. Besides high FIBCD1 expression, high CEA expression might also contribute to the diagnosis of gastric cancer and is a potential prognostic indicator. To our knowledge, this is the report that shows that FIBCD1 may hold great promise in predicting clinical outcomes of patients with gastric cancer.
Despite some merits, our study has some limitations. First, since this is a retrospective study, the sample size and quality of samples are limited. Second, the underlying mechanisms by which FIBCD1 affects the development and progression of gastric cancer have not been studied. Mechanistic studies should be performed to provide biological evidence of the role of FIBCD1 in gastric carcinogenesis. Third, immunohistochemical methods might not be able to precisely determine FIBCD1 expression in gastric cancer cells.
Biomarkers play an important role in early diagnosis, disease prevention, identification of drug targets, and other drug reactions. 31 Many patients with cancer are diagnosed at a late stage and have lost the chance for curative surgery. As a result, it is very likely that the cancer will recur due to the limited efficacy of systemic therapies for metastatic disease. For decades, biomedical scientists have been developing new methods to diagnose cancer at an early and curable stage as well as optimal treatments for individual patients. Improvement in early diagnosis will greatly increase the likelihood of benefits in clinical outcomes. Identifying biomarkers in the early stages of disease is important to determine the type and stage of disease and predict the results of different treatment options and the pharmacological response. 32 Thus, identifying effective biomarkers is very important for the development of new cancer management and treatment strategies.
In conclusion, our study demonstrates that the expression of FIBCD1 is significantly increased in gastric cancer tissues compared with normal tissues, and FIBCD1 overexpression is related to poor prognosis. FIBCD1 may be a novel prognostic marker in gastric cancer; however, the mechanisms of FIBCD1 function require further study in the future. 
